Product News and Articles

1 - 10 of 11 Articles 1 2 Next Next


Bio-Rad Announces FDA Clearance of its BioPlex 2200 ToRC IgM Assay

The BioPlex 2200 ToRC IgM Assay is a fully automated assay for the detection of IgM class antibodies to Toxoplasma gondii, rubella, and cytomegalovirus (CMV) offered in a multiplexed panel.
More »


Technical Support Update

Microsoft operating systems recently experienced a security vulnerability resulting from a widespread ransomware attack through Microsoft’s network environments on a global scale. Bio-Rad’s internal IT team has evaluated the technical details of the Microsoft security update and has approved the patch.
More »


Bio-Rad Launches Amplichek STI

Bio-Rad Launches Amplichek STI, the Third in a Series of Quality Controls for the Molecular Diagnostics Testing Market
More »


Bio-Rad Announces CE Marking of its BioPlex 2200 Syphilis Total & RPR Assay, a Novel Syphilis Testing Method

Bio-Rad Laboratories, Inc. today announced CE IVD marking for its BioPlex 2200 Syphilis Total & RPR assay, a novel universal testing method to aid in the diagnosis of syphilis infection.
More »


Bio-Rad Introduces its IH-1000 Blood Typing System for the U.S. Market

Bio-Rad Laboratories, Inc. today announced that it has received clearance from the U.S. Food and Drug Administration (FDA) for its IH-1000 blood typing instrument along with approvals for a wide range of associated gel cards and reagents for the U.S. blood typing market.
More »


Amplichek I Quality Control

Bio-Rad Launches Amplichek I Quality Control, the Second in a Series of Controls for the Molecular Diagnostics Testing Market
More »


Liquichek™ Maternal Serum II Control

Bio-Rad Announces the Release of Liquichek™ Maternal Serum II Control. The Multi-Constituent Control Offers Increased Efficiency and Confidence in Test Results.
More »


Bio-Rad Announces CE IVD Marking of its QX200 Droplet Digital PCR System for Use as an In Vitro Diagnostic

Researchers can use the QX200 system for highly-accurate detection and quantification of nucleic acids, aiding clinical decision-making in the treatment of diseases ranging from cancer to transplant rejection and viral infection.
More »


Bio-Rad Unveils Critical Raw Material Antigens for Diagnostic Uses

Bio-Rad announced the launch of human recombinant protein antigens, which expand the company’s critical raw material offering.
More »


Bio-Rad Mission: Control™ Risk Management Software Launched at AACC in Atlanta

Helps Laboratories Identify Best QC Rules and Frequency to Assess Risk of Reporting Incorrect Test Results
More »

Get Help
Sign Up for Bio-Rad Updates!
Enter your email address below to receive your choice of the latest news, promotions, and more.